Bayer's Kerendia reduced the risk of cardio death by 16% in tough-to-treat class of heart failure patients
Fierce Pharma
SEPTEMBER 1, 2024
With the heart failure (HF) patient population rapidly expanding, the timing is right for Bayer’s Kerendia (finerenone). | At the European Society of Cardiology (ESC) event, Bayer unveiled data from the 3 FINEARTS-HF trial that showed Kerendia reduced the risk of cardiovascular death, as well as well as first and recurrent HF events by 16% compared to placebo in patients with mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF).
Let's personalize your content